Intraperitoneal vancomycin‐induced immune thrombocytopenia
Seminars in Dialysis · 2022-01 · 35 (1) · 96-99
DOI: 10.1111/sdi.13024 ↗Kurz gefasst
Fallbericht in der Zeitschrift Seminars in Dialysis, online erschienen am 18.09.2021. Verfasst von Ahmet Murt und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Nephrology, Istanbul University-Cerrahpasa, Istanbul, Turkey. Hauptthemen laut MEDLINE: Peritonitis, Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Abstract (Originalsprache)
Vancomycin is one of the drugs used in the peritonitis treatment regimen of peritoneal dialysis patients. Intraperitoneal route is generally preferred to provide rapid elimination of infective agents. Systemic toxicities of certain drugs after intraperitoneal administration are not very clear. The same also applies to vancomycin, although it has a considerable amount of systemic absorption after intraperitoneal administration. We herein report a case of severe thrombocytopenia, which was seen during the treatment of a peritonitis attack in a peritoneal dialysis patient. Culture studies revealed methicillin resistant staphylococci as the causative agent and the patient received intraperitoneal vancomycin per sensitivity analysis. Thrombocyte levels dropped abruptly to 3,900/μl after 10 days of vancomycin treatment. Clinical criteria pointed out to vancomycin‐related immune thrombocytopenia. Platelet levels did not recover with initial dexamethasone treatment and platelet transfusions. In the meantime, the clinical course was also complicated with intracranial bleeding. Intravenous immunoglobulin treatment was applied and dexamethasone was switched to high‐dose methylprednisolone. This latter treatment generated a response and platelet levels gradually increased to normal levels. The patient could be discharged without any sequelae. There have been two previous intraperitoneal vancomycin‐related immune thrombocytopenia cases in the literature. Previous cases were reviewed, and the present case was given in comparison with the previous cases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Nephrology, Istanbul University-Cerrahpasa, Istanbul, Turkey.
- Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Hematology, Istanbul University-Cerrahpasa, Istanbul, Turkey.
- Cerrahpasa Medical Faculty, Department of Internal Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
ORCID-Profile: Ahmet Murt, Ayse Salihoglu, Muveddet Rezzan Ataman
Zitieren
APA
Murt, A., Ozkan Tekin, T., Guzel, S. S., Olcar, S., Salihoglu, A., & Ataman, M. R. (2022). Intraperitoneal vancomycin‐induced immune thrombocytopenia. Seminars in Dialysis, 35(1), 96-99. https://doi.org/10.1111/sdi.13024
Vancouver
Murt A, Ozkan Tekin T, Guzel SS, Olcar S, Salihoglu A, Ataman MR. Intraperitoneal vancomycin‐induced immune thrombocytopenia. Seminars in Dialysis. 2022;35(1):96-99. doi:10.1111/sdi.13024
BibTeX
@article{Murt2022,
author = {Murt, Ahmet and Ozkan Tekin, Tuba and Guzel, Suleyman Sami and Olcar, Sercan and Salihoglu, Ayse and Ataman, Muveddet Rezzan},
title = {Intraperitoneal vancomycin‐induced immune thrombocytopenia},
journal = {Seminars in Dialysis},
year = {2022},
volume = {35},
number = {1},
pages = {96--99},
doi = {10.1111/sdi.13024}
}
EUVIMED